Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

  • In development
  • GID-TA11232
  • Expected publication date: TBC

Documents

Documents created during the development process.

Draft guidance

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223

Topic selection